Besides an inhibitory effect on proliferation, migration, and invasion of breast cancer cells, the PI3K/mTOR-inhibitor PKI-402 was also shown to inhibit RANKL-mediated osteoclastogenesis and, thus, tumor-induced osteolysis through suppression of the PI3K/AKT/mTOR pathway [88]. Here, TNFSF11 is linked to breast carcinoma.